Cargando…
Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
Multiclass high-level transmitted HIV drug resistance is uncommon, and the selection of the optimal initial antiretroviral drug regimen may be challenging. We report a case of extensive transmitted multiclass resistance successfully treated with dolutegravir, tenofovir, and emtricitabine even though...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802795/ https://www.ncbi.nlm.nih.gov/pubmed/35111871 http://dx.doi.org/10.1093/ofid/ofab648 |
_version_ | 1784642746219233280 |
---|---|
author | Nagami, Ellen H Thakarar, Kinna Sax, Paul E |
author_facet | Nagami, Ellen H Thakarar, Kinna Sax, Paul E |
author_sort | Nagami, Ellen H |
collection | PubMed |
description | Multiclass high-level transmitted HIV drug resistance is uncommon, and the selection of the optimal initial antiretroviral drug regimen may be challenging. We report a case of extensive transmitted multiclass resistance successfully treated with dolutegravir, tenofovir, and emtricitabine even though the baseline genotype demonstrated full susceptibility to only 1 drug class, integrase strand transfer inhibitors. Our case highlights both the high resistance barrier of dolutegravir and the residual antiviral activity of nucleoside reverse transcriptase inhibitors despite extensive resistance on genotype. |
format | Online Article Text |
id | pubmed-8802795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-88027952022-02-01 Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance Nagami, Ellen H Thakarar, Kinna Sax, Paul E Open Forum Infect Dis Novel ID Cases Multiclass high-level transmitted HIV drug resistance is uncommon, and the selection of the optimal initial antiretroviral drug regimen may be challenging. We report a case of extensive transmitted multiclass resistance successfully treated with dolutegravir, tenofovir, and emtricitabine even though the baseline genotype demonstrated full susceptibility to only 1 drug class, integrase strand transfer inhibitors. Our case highlights both the high resistance barrier of dolutegravir and the residual antiviral activity of nucleoside reverse transcriptase inhibitors despite extensive resistance on genotype. Oxford University Press 2021-12-24 /pmc/articles/PMC8802795/ /pubmed/35111871 http://dx.doi.org/10.1093/ofid/ofab648 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Novel ID Cases Nagami, Ellen H Thakarar, Kinna Sax, Paul E Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance |
title | Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance |
title_full | Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance |
title_fullStr | Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance |
title_full_unstemmed | Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance |
title_short | Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance |
title_sort | sustained hiv viral suppression with dolutegravir, tenofovir, and emtricitabine as initial therapy despite high-level transmitted multiclass resistance |
topic | Novel ID Cases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802795/ https://www.ncbi.nlm.nih.gov/pubmed/35111871 http://dx.doi.org/10.1093/ofid/ofab648 |
work_keys_str_mv | AT nagamiellenh sustainedhivviralsuppressionwithdolutegravirtenofovirandemtricitabineasinitialtherapydespitehighleveltransmittedmulticlassresistance AT thakararkinna sustainedhivviralsuppressionwithdolutegravirtenofovirandemtricitabineasinitialtherapydespitehighleveltransmittedmulticlassresistance AT saxpaule sustainedhivviralsuppressionwithdolutegravirtenofovirandemtricitabineasinitialtherapydespitehighleveltransmittedmulticlassresistance |